

12

Measles

Measles vaccine introduced into National Immunisation Schedule -1985
MMR vaccine introduced-1988

NOTIFIABLE

In some circumstances, advice in these guidelines may differ from that in the Summary of Product Characteristics (SmPC) of the vaccines. When this occurs, the recommendations in these guidelines, which are based on current expert advice from NIAC, should be followed.

12.1. Introduction

Measles is an acute viral illness caused by a morbillivirus of the paramyxovirus family. There is only one antigenic type, with a number of genotypes. Measles is one of the world's most contagious diseases; one case of measles can infect 12-18 unvaccinated people. Even in high-resource countries, complications result in hospitalisation in up to a quarter of cases, and can lead to lifelong disability, from brain damage and blindness to hearing loss.

Humans are the only known host. Both infection and appropriate immunisation confer long-lasting and lifelong immunity in most people.

Worldwide, measles vaccination resulted in an 80% decline in measles deaths between 2000 and 2018, preventing an estimated 21 million deaths. Even though a safe and cost-effective vaccine is available, in 2017, there were 110 000 measles deaths globally, mostly among children under the age of five.

The WHO has a goal to achieve measles and rubella elimination in at least five WHO regions by the end of 2020.

12.2. Epidemiology


Globally, the number of measles cases has risen significantly since 2016. Many countries are in the midst of sizeable measles outbreaks, with all regions of the world experiencing sustained rises in cases. Between January 2016 and March 2019, 44,047 cases were reported from 30 EU/EAA countries, with a fourfold increase in cases noted between 2016 and 2017. Outbreaks have occurred in countries with high overall vaccination coverage, including Ireland.

In Ireland, between 1948 and 1984 an average of over 5,000 cases were reported annually. The incidence declined dramatically after the introduction of monocomponent measles vaccine in 1985, from 10,000 cases in 1985 to 201 cases in 1987.

An outbreak of measles in 1993 affected more than 4,000 people and in 2000 over 1,600 cases of measles were reported, with 3 associated deaths. Additional local and national outbreaks have occurred since then, predominantly affecting sub groups of the population with low vaccination coverage (Figure 12.1).

Figure 12.1 Number of measles notifications in Ireland, 1948-2018


Source: CIDR HPSC



From 2001-2018 there were 2,837 cases of measles notified in Ireland. Incomplete vaccine coverage combined with a pool of susceptible unvaccinated older children resulted in rapid spread of the infection during these outbreaks (Figure 12.2).

Figure 12.2 Number of measles notifications in Ireland, 2000 - 2018

Source: CIDR HPSC



Transmission of measles is by airborne or droplet infection. It is spread by coughing and sneezing, close personal contact or direct contact with infected nasal or throat secretions.

The virus remains active and contagious in the air or on infected surfaces for up to 2 hours. It can be transmitted by an infected person from 4 days prior to the onset of the rash to 4 days after the rash erupts.

12.3. Effects of measles

The incubation period averages 10-12 days, and exposure to rash onset averages 14 days (range 7-21 days). The prodrome (before rash onset) usually lasts 2-4 days (range 1-8 days).

This phase is characterised by fever, significant malaise, anorexia, rhinitis, conjunctivitis and cough. The severity of conjunctivitis is variable and may be accompanied by photophobia. Respiratory symptoms result from mucosal inflammation due to viral infection of epithelial cells. Fever is typically present and may be as high as 40°C. The prodromal symptoms typically intensify a few days before the rash appears.

The erythematous, maculopapular rash first appears behind the ears and spreads to the face, trunk and limbs over 3-4 days. The rash may become confluent in places. After 3 to 4 days, the rash begins to fade, in the order that it appeared, leaving a temporary brownish discolouration.

Chapter 12 Measles

Koplik spots (small red spots with white centres) may appear on the buccal mucosa near the exit of the parotid duct, from 1-2 days before to 1-2 days after the rash appears.

Clinical improvement usually begins within 48 hours of the appearance of the rash. The cough may persist for 1-2 weeks. Fever lasting longer than 3 to 4 days after rash onset suggests the presence of a measles-associated complication.

Approximately 30% of measles cases have one or more complications, which are more common in those aged <5 and >20 years of age. These complications include otitis media (1/10-15 cases), diarrhoea (1/16), pneumonia (1/15), convulsions (1/200), death (1/500 - 800) encephalitis (1/1,000) and subacute sclerosing panencephalitis (1/25,000).

Measles infection induces transient immune compromise with decreased numbers of CD4 T cells in lymphoid tissue for weeks and leucopenia for about a week following infection. This contributes to the susceptibility to serious bacterial infection that may follow measles.

There are three types of measles encephalitis:

- *Measles inclusion body encephalitis* occurs in 1-3/1,000 children concurrent with measles infection. It is characterised by acute neurological compromise, loss of consciousness, seizures and progressive neurological damage. Ten to 15% of these children die and 25% have permanent neurological damage.
- *Acute demyelinating encephalomyelitis* occurs about one week after the onset of the rash in approximately 1/1,000 cases, has a mortality of about 15% and results in residual neurological sequelae in 20-40% of survivors.
- *Sub-acute sclerosing panencephalitis (SSPE)*, a degenerative CNS disease presenting usually 7-10 years after infection and progressing to death, occurs in 1/25,000 infected people. If measles infection occurs in children under 5 years of age the rate of SSPE is 1-3/3,000. If infection occurs in children under 1 year of age, the rate is 1/600, which is 16 times greater than with infection occurring over 5 years of age.

The risk of encephalitis following administration of MMR vaccine (<1/10 million doses) is far below the risk of encephalitis caused by natural diseases.

Complications and mortality rates from measles are high in the immunocompromised, the malnourished and in those with vitamin A deficiency. Severe complications may occur in up to 80% of these individuals, with case-fatality rates of 70% in those with cancer.

The case fatality rate is highest in children under 1 year of age, lowest in those aged 1-9 and rises again in teenagers and adults. Pneumonia accounts for 56-86% of measles-associated deaths. Death occurred in 1 in 500 notified cases in Ireland in the outbreak of 2000.

Modified measles occurs primarily in those who receive immunoglobulin as post-exposure prophylaxis or in infants with residual maternal antibodies. It is characterised by a prolonged incubation period, mild prodrome and a sparse, discrete rash of short duration. A similar illness has been reported in previously vaccinated persons who develop measles.

12.4. Measles vaccines

Monocomponent measles vaccine was introduced in Ireland in 1985. In 1988 a combined measles, mumps and rubella vaccine (MMR) was introduced for children aged 12-15 months. In 1992 a second dose of MMR vaccine was recommended for children at 10-14 years of age.

In 1995 a measles and rubella (MR) vaccination catch-up campaign was carried out. In 1999 the age for the second dose of MMR vaccine was reduced to 4-5 years. In 2010 a MMR vaccination catch-up campaign for children in the senior cycle (last three years) of second level schools was undertaken in response to a national mumps outbreak. In 2012-14 MMR catch-up vaccination campaigns were carried out in second level and primary schools in response to sub optimal vaccine uptake in these age groups.

Uptake rate of at least 95% with 2 doses of MMR vaccine at ≥ 12 months of age and least 4 weeks apart is required to halt endemic transmission of the virus and thus eliminate measles.

Measles vaccines are only available as MMR (Measles, Mumps and Rubella vaccine). The vaccines contain live attenuated measles, mumps and rubella viruses that are cultured separately and combined.

Two vaccines are available in Ireland:

MMRvaxPRO® (MSD)

Priorix® (GSK)

12.4.1. Licensed indications: active immunisation of children aged 9 months or older, adolescents, and adults against measles, mumps and rubella.

MMR vaccines must be kept refrigerated at +2 to +8°C and protected from light. They should be used within 1 hour of reconstitution. Failure to adhere to these recommendations can result in loss of vaccine potency and diminished effectiveness.

Chapter 12 Measles

If a vaccine has been frozen it should not be used.

Approximately 95-98% of recipients develop immunity to measles after one dose of MMR vaccine. Over 99% of those who receive two doses of measles vaccine ≥ 12 months of age and ≥ 4 weeks apart will develop measles immunity which is lifelong in most people. Breakthrough infections are very rare and are generally milder than in unvaccinated persons.

Lower rates of seroconversion occur in those under 12 months of age, because of maternal antibodies.

Laboratory investigation to determine vaccine response is not routinely recommended.

An up-to-date list of licensed vaccines can be accessed on the HPRA website www.hpra.ie

A list of the vaccines currently available from the National Cold Chain Service can be found at www.immunisation.ie

There is no evidence to recommend the use of single vaccines against measles, mumps and rubella instead of the combination MMR vaccine. No single antigen vaccines are licensed in Ireland.

12.4.2. Dose and route of administration

The dose is 0.5 ml by intramuscular injection into the deltoid or the anterolateral thigh. It may be given SC to those with significant thrombocytopenia or bleeding disorder.

Alcohol swabbing of the injection site should be avoided as alcohol can inactivate the MMR vaccine. If an alcohol swab is used, injection should be delayed for 30 seconds to ensure the alcohol will have evaporated.

MMR vaccine can be given at the same time as any other vaccine except yellow fever vaccine. If not given on the same day they must be separated by at least 4 weeks*.

*Co-administration of MMR and yellow fever vaccines can lead to suboptimal antibody responses to mumps, rubella and yellow fever antigens.

If rapid protection is required the vaccines may be given at any interval and an additional dose of MMR given at least 4 weeks later.

12.5 Recommendations

12.5.1 Routine childhood vaccination: All children at 12 months of age should receive an MMR vaccine, with a second dose at 4-5 years of age.

If protection is urgently required the second dose can be given 4 weeks after the first.

Children receiving their first dose of MMR vaccine \geq 4-5 years of age should be given MMR vaccine as soon as possible and a second dose 4 weeks later.

MMR vaccine can be given to those who have a history of measles, mumps or rubella infection.

12.5.2 Vaccination during measles outbreaks

Outbreaks of measles may be controlled by immunising all susceptible individuals within 3 days of contact, as vaccine - induced immunity develops more rapidly than that following infection.

When measles outbreaks occur, susceptible persons aged \geq 6 months should be given MMR vaccine within 72 hours of contact with a case.

If a person had no previous measles vaccine, a second dose is given one month later.

During an outbreak, particularly if there are high attack rates in younger infants, MMR vaccine may be given as young as 6 months of age. However, maternal antibodies may compromise the response to the vaccine. Therefore, infants vaccinated before their first birthday should have a repeat vaccination at 12 months of age, at least 4 weeks after the first vaccine, with a further dose at 4-5 years of age.

Some susceptible persons may require HNIG (see below).

12.5.3 Vaccination for those travelling to areas where measles is endemic or where outbreaks are occurring:

- i. **Infants aged 6 months to <12 months** should receive one dose of MMR vaccine. A dose given <12 months of age does not replace the dose recommended at 12 months of age. If a dose of MMR vaccine is given before the first birthday, either because of travel to an endemic country or because of a local outbreak, two further doses should be given \geq 12 months of age (at least 4 weeks after the first dose) and 4 to 5 years of age.

ii. Children aged ≥ 12 months

a) *if unvaccinated* should receive two doses of MMR vaccine separated by at least 4 weeks. To ensure optimal protection, the second dose should be given ≥ 2 weeks prior to travel.

b) *who have received one dose of MMR vaccine* should receive a second dose ≥ 4 weeks later and ideally ≥ 2 weeks prior to travel.

iii. **Teenagers and adults without evidence of measles vaccination** should receive two doses of MMR vaccine separated by at least 4 weeks.

12.5.4 Migrants, ethnic minority groups and those coming from low resource countries

are less likely to have been vaccinated with MMR. Without documented evidence of measles vaccination they should be offered two doses of MMR vaccine at least 4 weeks apart.

12.5.5 All HCWs, both clinical and non-clinical, who have direct patient contact should be immune to measles, mumps and rubella. This applies to roles in which:

- their work requires face to face contact with patients, or
- their normal work location is in a clinical area such as a ward, emergency department or outpatient clinic, or
- their work frequently requires attendance in clinical areas.

Acceptable presumptive evidence of immunity against measles includes at least one of the following:

- Written documentation of two doses of a measles containing vaccine
- Laboratory evidence of immunity
- Laboratory confirmations of measles infection
- Birth in Ireland before 1978. Most adults born in Ireland before 1978 are likely to have had measles infection. If there is doubt about measles status and if vaccination history cannot be validated, assume susceptibility and give MMR vaccine unless contraindicated.

Serological testing after routine MMR vaccination is not recommended.

Antibody response to the mumps and rubella components of the MMR vaccine does not develop quickly enough to provide effective prophylaxis after exposure to suspected mumps or rubella.

12.6 Contraindications

- Anaphylaxis to any of the vaccine constituents
- Significant immunocompromise (see Chapter 3)
- Pregnancy. Furthermore, pregnancy should be avoided for 1 month after MMR vaccine.

The following are NOT contraindications to MMR vaccine

- Allergy to egg, including anaphylaxis following egg. Currently available MMR vaccines do not contain significant amounts of egg cross-reacting proteins and recent data suggest that anaphylaxis following MMR vaccine is associated with other vaccine components (e.g. gelatin or Neomycin).
- Breast-feeding.
- HIV-positive patients who are not severely immunocompromised (see Chapter 3).
- Personal or family history of convulsions.
- Immunodeficiency in a family member or household contact.
- Previous MMR vaccination.
- Recent injection of anti-RhD immunoglobulin
- Hereditary fructose intolerance.

12.7 Precautions

- Acute severe febrile illness, defer until recovery.
- Injection with another live vaccine within the previous 4 weeks.
- Recent administration of blood or blood products. These may contain significant levels of virus-specific antibodies, which could prevent vaccine virus replication. MMR vaccine should be deferred for 6 months after packed red-cell, whole-blood transfusion and HNIG. If the MMR vaccine is administered within these timeframes, a further 1 or 2 doses as required should be given.
- MMR vaccine should not be administered on the same day as yellow fever vaccine as co-administration of these two vaccines can lead to suboptimal antibody responses to mumps, rubella and yellow fever antigens. If rapid protection is required the vaccines may be given at any interval and an additional dose of MMR vaccine given at least 4 weeks later.
- Tuberculin skin testing should be deferred for at least 4 weeks after MMR vaccine as the measles vaccine can reduce the tuberculin response and could give a false negative result.
- Those who developed thrombocytopenia within 6 weeks of their first dose of MMR vaccine should undergo serological testing to decide whether a

Chapter 12 Measles

second dose is necessary. The second dose is recommended if the patient is not fully immune to the 3 component viruses.

12.8 Adverse reactions

Local: very common: erythema at injection site.
common: soreness, swelling.

General: common: rhinitis, rash.

“Mini-measles” may occur 6-10 days after immunisation and consists of mild pyrexia and an erythematous rash.

‘Mini-mumps’ with salivary gland swelling may rarely occur during the third week after immunisation.

The rubella component may occasionally produce a rash, mild arthralgia, and lymph-node swelling 2-4 weeks post-vaccination, particularly in post-pubertal females (up to 25% of recipients). The incidence is lower than after natural disease.

Febrile convulsions occur rarely (< 1/1,000 children).

Very rarely, erythema multiforme, thrombocytopenia and nerve deafness have been reported.

There is no evidence of congenital rubella syndrome or increase in other teratogenic effects in women inadvertently given MMR vaccine. However, pregnancy remains a contraindication to its administration.

Scientific evidence confirms that there is no causal relationship between the MMR vaccine and autism or inflammatory bowel disease.

12.9. Post Exposure Prophylaxis of Measles

Note: In this section the term ‘exposure’ refers to ‘significant’ exposure.

Exposure to measles is considered significant if:

a susceptible individual is exposed to a confirmed or probable case of measles during the infectious period (4 days before to 4 days after rash onset) in any of the following ways:

- face-to-face contact of any duration
- an immunocompetent individual is in a room with the case for more than 15 minutes. This includes those who, within the preceding 6 days, may have been exposed to measles in an Emergency Department (ED) or Out Patient

Department (OPD) setting where the intensity of such exposure cannot accurately be judged.

- an immunocompromised person is in a room with the case for any duration or enters a room vacated by a case within two hours of the case leaving the room.

12.9.1 Groups at increased risk for severe illness and complications include:

- infants younger than 12 months of age
- pregnant women without measles immunity
- those who are severely immunocompromised (see Chapter 3)

Household contacts of a case have higher intensity exposure and an increased risk of more severe disease than non-household contacts.

Most Irish-born mothers, born after 1985 (when routine measles vaccination was introduced), are unlikely to have had measles infection. The levels of transplacentally acquired antibodies in infants born to vaccinated mothers tend to be lower than in infants of mothers who had natural infection and to wane more rapidly, usually declining within weeks of birth. If mothers have had measles infection, maternal antibodies may protect the infant for a few months after birth.

Immunity from MMR vaccine develops more rapidly than immunity from infection and thus MMR vaccine can be successfully used to prevent infection following exposure. When used for prophylaxis, MMR vaccine should be given within 3 days of exposure.

Maternal antibodies can interfere with an infant's response to MMR vaccine for up to 12 months of age. Thus, Infants who receive MMR vaccine <12 months of age need two additional doses of MMR vaccine, at ≥ 12 months (at least 4 weeks after first dose.) and 4-5 years of age, in accordance with the national schedule.

Human Normal Immunoglobulin (HNIG) contains sufficient anti-measles antibodies to prevent or ameliorate infection in susceptible persons. It is available for subcutaneous, intramuscular or intravenous (IVIG) use. Ideally it should be given within 3 days of exposure, but may provide some protection if given within 6 days of exposure.

12.10 Post exposure prophylaxis of vulnerable contacts following significant exposure:

12.10.1 Infants (see Table 12.1)

• **aged <6 months**

- i. *Household or household type exposure:* contacts should receive HNIG, ideally within 3 days of exposure. It can be given with potential benefit up to 6 days following exposure.
- ii. *Non-household exposure* (this includes those who, within the preceding 6 days, may have been exposed to measles in an Emergency Department (ED) or Out Patient Department (OPD) where the intensity of such exposure cannot be accurately judged):
 - If the infant's and mother's measles IgG status can be ascertained within 3 days and is positive, HNIG is not indicated. If the measles IgG result is weakly positive, equivocal or unknown, HNIG is recommended, and should be given within 3 days. It can be given with potential benefit up to 6 days following exposure.

• **aged 6 to <9 months**

- i. *Household or household type exposure:*
 - **exposure within the preceding 3 days** - give MMR vaccine.
 - **exposure between 3-6 days previously** (i.e. days 4 – 6 post exposure) and MMR vaccine has not been given within 3 days of exposure - give HNIG if practicable.

Those who have received HNIG should wait 6 months before receiving routine MMR vaccination.

ii. *Non-household exposure:*

- these infants are less likely to have the intensity of exposure to develop severe disease. They should receive MMR vaccine within 3 days of exposure. If MMR vaccine cannot be given within 3 days of exposure, HNIG should be considered up to 6 days.

• **aged 9 months or older**

Household or non-household exposure

These contacts should receive MMR vaccine. Ideally the vaccine should be administered within 3 days; it should still be offered at any interval following exposure in order to offer protection from future exposure.

Table 12.1. Management of infants with significant exposure to measles

Age	Management	
	Household or household type exposure	Non household exposure
< 6 months	Give HNIG within 3 days (can be given up to 6 days after exposure)	Give HNIG within 3 days (can be given up to 6 days after exposure), unless infant and mother have positive measles IgG serology. <i>If the Measles IgG result is equivocal weakly positive or unknown, HNIG is recommended.</i>
6 – <9 months	Give MMR vaccine within 3 days. Give HNIG if within 3-6 days of exposure. ¹	Give MMR vaccine within 3 days. If not possible, consider HNIG up to 6 days post exposure. ²
≥ 9 months	Administer MMR vaccine, ideally within 3 days of exposure. ³	

¹ Children who have received HNIG should wait 12 months before routine MMR vaccination.

² If MMR vaccine is given <12 months of age, two further doses are required, at ≥12 months and at least 4 weeks apart.

³ If exposure may be ongoing (e.g. a single case in a nursery or during a community outbreak), MMR vaccination >3 days may provide protection from subsequent exposures. HNIG is not routinely recommended for this age group in the absence of other indications (e.g. immunocompromise).

12.10.2. Pregnancy

HNIG should be administered to pregnant women without evidence of measles immunity who have had significant exposure to measles. Ideally it should be given within 3 days of exposure, but can be given up to 6 days. Women with measles IgG titres reported as 'positive' or 'weak positive' are likely to have measles infection-induced immunity and do not need HNIG.

12.10.3. Immunocompromised persons (see Chapter 3)

Most immune suppressed individuals can maintain protective antibodies from prior vaccination or natural infection and can be managed based on history of natural infection or prior measles antibody test results.

If prior documentation of measles immunity is available, post exposure prophylaxis is not required. If no such documentation is available, urgently assess serologic status and give post exposure HNIG prophylaxis to exposed individuals who are antibody negative. HNIG should ideally be given within 3 days of exposure but can be given up to 6 days.

People with leukaemia, lymphoproliferative disorder, or post solid organ transplant, who are ≥12 months post haematopoietic stem cell transplant (HSCT) or ≥6 months following completion of biologic therapies, or who have

AIDS may lose protective antibodies over time. They should be urgently assessed for measles immunity at the time of exposure *regardless of past vaccination history or previous serologic test result*. If measles IgG is detected, post exposure prophylaxis is not required. If seronegative, offer post exposure prophylaxis with HNIG.

Exposed individuals with *severely* compromised immune systems, i.e. those who have received a HSCT within the preceding 12 months and those with severe primary immunodeficiency), should receive **IVIG, not IM or SC HNIG**, regardless of immunologic or vaccination status.

Immunocompromised patients who are regular recipients of immunoglobulin therapy do not require additional prophylaxis if they have received a dose of HNIG within 3 weeks prior to exposure.

NB: Post-exposure prophylaxis with Immunoglobulin or MMR vaccine is not always fully effective in preventing measles infection. Therefore, exposed persons who receive post-exposure prophylaxis remain an infection control risk. They should be managed in accordance with usual infection control procedures following a measles exposure.

12.12 HNIG preparations, dose and administration

Although HNIG products are not licensed for post exposure prophylaxis, their use has proven effective in preventing or attenuating measles if given within 6 days of exposure.

Peak levels of HNIG are obtained within minutes of IV administration, approximately 2 days after IM injection and 2-3 days after SC administration. It should ideally be given SC or IM within 72 hours of exposure to a case of measles from 4-5 days before to 4 days after the measles rash appears. There is no consistent evidence regarding the efficacy of SC immunoglobulin received 4-6 days after exposure to a case of measles, and its use is primarily to reduce the severity of disease in vulnerable contacts.

It can be given IV up to 6 days after exposure, allowing time for assessment of immunity status in most instances.

12.12.1 Preparations

Subcutaneous use

Four HNIG products are licensed and available in Ireland for subcutaneous (SC) administration - **Cuvitru**[®] (20%), **Gammanorm**[®] (16.5%), **Hizentra**[®] (20%), and **HyQvia**[®] (10%). Following SC administration, peak serum IgG levels are reached by Hizentra[®] in approximately 2 days, by Cuvitru[®] in 3 days, by HyQvia in 3-5 days and by Gammanorm[®] in 4-6 days.

When available, either Cuvitru® or Hizentra® are recommended, because of the smaller volume required, and the earlier peak serum levels achieved compared to lower concentration products.

Intramuscular use

This route may be used if SC or IV administration is not practicable. Gammanorm® is the only HNIG preparation licenced for IM administration.

Intravenous use

A number of IVIG products (e.g. Kiovig®, Flebogamma®, Intratect®) are available through hospital pharmacies. IVIG is recommended for use in immunocompromised contacts (see Chapter 3). If SC or IM HNIG is not available, in certain high-risk situations IVIG can be substituted.

12.12.2 Dose for measles prophylaxis

Dose recommendations for post exposure prophylaxis against measles are not well established. Based on available evidence the following doses are recommended:

Table 12.2. Dose of subcutaneous HNIG recommended for measles contacts aged <9 months.

Infant weight (kg)	20% HNIG (Cuvitru® Hizentra®)
3-<4	3ml
4-<5	3.5ml
5-<6	4.5ml
6-<7	5ml
7-<8	6ml
8-<9	6.5ml
9-<10	7.5ml
10-<11	8ml
11-<12	9ml
12 -<14	10ml

Dose of HNIG for measles contacts ≥ 9 months:

- subcutaneous or IM: 0.2g/kg
- IV: 0.15g/kg (can round up to use all of the vial)
higher doses (0.4 – 0.5g/kg) are generally used for replacement therapy.

12.12.3 Administration

These preparations should be given by SC infusion, at an initial rate of not more than 10ml/hour/infusion site. More than one pump can be used simultaneously, to shorten the infusion time. If tolerated, the rate can be increased at intervals of ≥ 10 minutes to a maximum of 20ml/hour/ site. The infusion site can be changed every 5 to 10 ml.

Always consult the SmPC for information about product usage, administration, adverse events etc.

Bibliography

American Academy of Pediatrics (2018). Red Book: Report of the Committee on Infectious Diseases. 31st ed. Elk Grove Village, IL: American Academy of Pediatrics.

Canadian Immunization Guide 2016. Blood Products, Human Immunoglobulin and Timing of Immunization.

www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-11-blood-products-human-immune-globulin-timing-immunization.html#p1c10t1

Centers for Disease Control (CDC). Subacute sclerosing panencephalitis surveillance - United States. MMWR Morb Mortal Wkly Rep 1982; 31:585.

Centers for Disease Control (2015). Epidemiology and prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 13th ed. Washington DC: Public Health Foundation.

Centers for Disease Control and Prevention (2017). Immunoglobulin (IG) as post-exposure prophylaxis.

<https://www.cdc.gov/measles/hcp/index.html>

Centers for Disease Control and Prevention (2018). Pink Book-Measles.

<https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/meas.pdf>

Centers for Disease Control and Prevention (2019). Timing and Spacing of Immunobiologics.

www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html

www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/mmr_ig.pdf

Cherry JD (2009). Measles virus. In: Textbook of Pediatric Infectious Diseases, 6th ed, p.2427.

Clark AT, et al. (2010). British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy. Clin Exp Allergy 40(8):1116-29.

Department of Health UK (2013). Immunisation against Infectious Diseases (The Green Book) www.dh.gov.uk/greenbook

European Center for Disease Prevention and Control (2019).. Who is at risk for measles in the EU/EAA.

<https://ecdc.europa.eu/sites/portal/files/documents/RRA-Measles-EU-EEA-May-2019.pdf>

Orenstein WA et al (2018). Measles and Rubella Global Strategic Plan 2012–2020 midterm review report: Background and summary. *Vaccine*, 36: A35-42.

Public Health England (2017). Guidelines on Post-Exposure Prophylaxis for measles

www.gov.uk/government/uploads/system/uploads/attachment_data/file/637003/Guidance_for_measles_post-exposure_prophylaxis.pdf

Public Health England (2019). Guidelines on Post-Exposure Prophylaxis for measles.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/814203/Guidance_for_measles_post-exposure_prophylaxis.pdf

Schönberger K et al (2013). Epidemiology of Subacute Sclerosing Panencephalitis (SSPE) in Germany from 2003 to 2009: A Risk Estimation. *PLoS One*. 2013; 8(7): e68909. doi: 10.1371/journal.pone.0068909

The Australian Immunisation Handbook (2017). Passive immunisation using immunoglobulin preparations.

www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part5~handbook10-5-1